Spotlight on Neurology

Vera Bril, MD, FRCPC
Credits: 1.0 CME
A Review of Disease Mechanisms and Current and Emerging Treatment Options for Generalized Myasthenia Gravis
Vera Bril, MD, FRCPC
The CME Institute of Physicians Postgraduate Press, Inc.

A Review of Disease Mechanisms and Current and Emerging Treatment Options for Generalized Myasthenia Gravis

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: June 21, 2022
Expires: June 20, 2023
60 minutes to complete

Accredited By

The CME Institute of Physicians Postgraduate Press, Inc.

Target Audience

Neurology, neuromuscular, neuroimmunology, & neuro-ophthalmology advanced care practitioners in North America, Europe, and Japan

Learning Objectives

  • Consider actions of novel medications in treatment decisions for patients with gMG (including IgG and AChR antibodies, FcRn modulation)
  • Counsel patients on the changing landscape of gMG treatment
  • Incorporate evidence on efficacy and safety into the process of tailoring appropriate therapies for patients with gMG, both with current treatments and as novel ones become available

Activity Description

On-demand webcast featuring faculty presentations and case questions from the webinar.

Statement of Educational Need

Treatment of gMG is not one-size-fits-all because of patients’ varied symptoms and disease pathophysiology. Despite numerous available therapies, the current treatment landscape for gMG has left many patients with unmet efficacy needs and considerable side effect burden. Research in gMG has grown substantially in recent years. Clinicians need awareness of disease mechanisms and education on the efficacy and safety of current and emerging therapies to improve outcomes for patients with gMG. This activity was designed to meet the needs of participants in CME activities provided by the CME Institute of Physicians Postgraduate Press, Inc., who have requested information on gMG.

Chair

Vera Bril, MD, FRCPC
Division of Neurology
University of Toronto and University Health Network
Toronto, Ontario, Canada

Dr. Bril has served as a consultant for argenx, Alexion, Alnylam, Ackea, Ionis, Immunovant, Sanofi, Roche, UCB, Momenta, CSL, Takeda, Octapharma, NovoNordisk, Grifols, Janssen; received grant/research support from argenx, Alexion, UCB, Takeda, CSL, Immunovant, Momenta, Ionis, Pharnext; received honoraria from argenx, Alexion, Alnylam, Ackea, Immunovant, Momenta, Ionis, Pharnext; and has served on speakers/advisory boards for argenx, Alexion, Alnylam, Ackea, Ionis, Immunovant, Sanofi, Roche, UCB, Momenta, CSL, Takeda, Octapharma, NovoNordisk, Grifols, Janssen.

Faculty

Nicholas J. Silvestri MD, FAAN
University at Buffalo Jacobs School of Medicine and Biosciences
Buffalo, New York

Dr. Silvestri has served as a consultant for argenx and has served on speakers/advisory boards for Alexion, argenx, Immunovant, UCB, and Strongbridge.


Carolina Barnett-Tapia, MD, PhD
Division of Neurology
University of Toronto and University Health Network
Toronto, Ontario, Canada

Dr. Barnett-Tapia has served as a consultant for argenx and Alexion; received grant/research support from the US Department of Defense, MGNet, Muscular Dystrophy Canada, and Grifols; and served on the speaker/advisory board for Sanofi.

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

To obtain credit for this activity, study the material and complete the CME Posttest and Evaluation.

Instructions for Receiving Credit

In order to be awarded credit and/or a certificate for this activity, learners must study the material, participating in all course pages, complete the Posttest, and complete the Evaluation.

Statement of Commercial Support

Supported by an educational grant from argenx.

Disclaimer Statement/Disclosure of Unlabeled Use

The faculty members have determined that, to the best of their knowledge, corticosteroids, azathioprine, mycophenolate, methotrexate, cyclosporine, tacrolimus, IVIG, SCIG, PLEX, rituximab, rozanolixizumab, zilucoplan, nipocalimab, and RVT-1401 are not approved by the US Food and Drug Administration for the treatment of myasthenia gravis.

Contact Information for Questions About the Activity

cme@cmeinstitute.com

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: June 21, 2022
Expires: June 20, 2023
60 minutes to complete

Accredited By

The CME Institute of Physicians Postgraduate Press, Inc.

Target Audience

Neurology, neuromuscular, neuroimmunology, & neuro-ophthalmology advanced care practitioners in North America, Europe, and Japan

Learning Objectives

  • Consider actions of novel medications in treatment decisions for patients with gMG (including IgG and AChR antibodies, FcRn modulation)
  • Counsel patients on the changing landscape of gMG treatment
  • Incorporate evidence on efficacy and safety into the process of tailoring appropriate therapies for patients with gMG, both with current treatments and as novel ones become available

Activity Description

On-demand webcast featuring faculty presentations and case questions from the webinar.

Statement of Educational Need

Treatment of gMG is not one-size-fits-all because of patients’ varied symptoms and disease pathophysiology. Despite numerous available therapies, the current treatment landscape for gMG has left many patients with unmet efficacy needs and considerable side effect burden. Research in gMG has grown substantially in recent years. Clinicians need awareness of disease mechanisms and education on the efficacy and safety of current and emerging therapies to improve outcomes for patients with gMG. This activity was designed to meet the needs of participants in CME activities provided by the CME Institute of Physicians Postgraduate Press, Inc., who have requested information on gMG.

Chair

Vera Bril, MD, FRCPC
Division of Neurology
University of Toronto and University Health Network
Toronto, Ontario, Canada

Dr. Bril has served as a consultant for argenx, Alexion, Alnylam, Ackea, Ionis, Immunovant, Sanofi, Roche, UCB, Momenta, CSL, Takeda, Octapharma, NovoNordisk, Grifols, Janssen; received grant/research support from argenx, Alexion, UCB, Takeda, CSL, Immunovant, Momenta, Ionis, Pharnext; received honoraria from argenx, Alexion, Alnylam, Ackea, Immunovant, Momenta, Ionis, Pharnext; and has served on speakers/advisory boards for argenx, Alexion, Alnylam, Ackea, Ionis, Immunovant, Sanofi, Roche, UCB, Momenta, CSL, Takeda, Octapharma, NovoNordisk, Grifols, Janssen.

Faculty

Nicholas J. Silvestri MD, FAAN
University at Buffalo Jacobs School of Medicine and Biosciences
Buffalo, New York

Dr. Silvestri has served as a consultant for argenx and has served on speakers/advisory boards for Alexion, argenx, Immunovant, UCB, and Strongbridge.


Carolina Barnett-Tapia, MD, PhD
Division of Neurology
University of Toronto and University Health Network
Toronto, Ontario, Canada

Dr. Barnett-Tapia has served as a consultant for argenx and Alexion; received grant/research support from the US Department of Defense, MGNet, Muscular Dystrophy Canada, and Grifols; and served on the speaker/advisory board for Sanofi.

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

To obtain credit for this activity, study the material and complete the CME Posttest and Evaluation.

Instructions for Receiving Credit

In order to be awarded credit and/or a certificate for this activity, learners must study the material, participating in all course pages, complete the Posttest, and complete the Evaluation.

Statement of Commercial Support

Supported by an educational grant from argenx.

Disclaimer Statement/Disclosure of Unlabeled Use

The faculty members have determined that, to the best of their knowledge, corticosteroids, azathioprine, mycophenolate, methotrexate, cyclosporine, tacrolimus, IVIG, SCIG, PLEX, rituximab, rozanolixizumab, zilucoplan, nipocalimab, and RVT-1401 are not approved by the US Food and Drug Administration for the treatment of myasthenia gravis.

Contact Information for Questions About the Activity

cme@cmeinstitute.com

Neurology Presentations

2.0 CME / CNE
Vindico Medical Education
MS Forum® VIII: Novel Advances and the Optimization of MS Treatments

MS Forum® VIII: Novel Advances and the Optimization of MS Treatments

Start

Activity Details

Free CME/CNE
1.75 AMA PRA Category 1 Credit(s)
1.75 ANCC Contact Hour(s)
Released: November 30, 2022
Expires: November 29, 2023
1.75 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, neurology nurses, neurology nurse practitioners, and other health care professionals involved in the management of patients with multiple sclerosis (MS).

Learning Objectives

Physicians and APPs
Upon successful completion of this activity, physicians should be better able to:

  1. Assess the most recent clinical and/or real-world evidence regarding the safety and efficacy of current and emerging disease-modifying therapies (DMTs) for the treatment of patients with MS.
  2. Identify clinical trends and controversies in MS that may have implications on clinical decision-making.
  3. Review data regarding the impact of DMTs on overall immune response to vaccines (including non-COVID-19 vaccines) into clinical decision-making.

Nurses
Upon successful completion of this activity, nurses should be better able to:

  1. Assess the most recent clinical and/or real-world evidence regarding the safety and efficacy of current and emerging DMTs for the treatment of patients with MS.
  2. Identify clinical trends and controversies in MS that may have implications on clinical decision-making.
  3. Review data regarding the impact of DMTs on overall immune response to vaccines (including non-COVID-19 vaccines) into clinical decision-making.

Activity Description

Multiple sclerosis (MS) is a chronic, often disabling disease that attacks the central nervous system. The management of patients with MS is highly complex, and the development of disease-modifying therapies (DMTs) has dramatically altered the treatment paradigm. The live, virtual “MS Forum® VIII: Advancing MS Care in the Pandemic Era” is a 3-part, multi-accredited webinar series that aims to provide health care professionals with guidance on the appropriate use of therapies and strategies for delivering individualized care to patients with MS. This session will incorporate didactic and case presentations covering vaccines in MS, differentiating DMTs, novel advances in MS, as well as a focus on Bruton tyrosine kinase inhibitors.

Agenda

Introduction – Overview of objectives and activation of learning
Patricia K. Coyle, MD

The Year in Review: Novel Advances in MS
Clyde E. Markowitz, MD

Vaccines in MS: Immunization Protocols in Patients With MS
Bruce A. Cohen, MD

Clinical Cases: Vaccination Vacillation
Bruce A. Cohen, MD

Differentiating DMTs to Optimize Treatment Individualization
Stephen Krieger, MD

Focus on BTK Inhibitors: Clinical Updates
Patricia K. Coyle, MD

Clinical Case: Selecting Optimal Treatment for a Patient With MS
Patricia K. Coyle, MD

Activity Chair

Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Stony Brook MS Comprehensive Care Center
Stony Brook University
Stony Brook, NY

Relevant Financial Disclosures
Consultant: Accordant, Biogen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Mylan, Novartis, Sanofi, TG Therapeutics
Independent Research Contractor: Actelion, Alkermes, Celgene, Genentech/Roche, Novartis, Sanofi Genzyme

Faculty

Bruce A. Cohen, MD, FAAN, FANA, FACP
Professor of Neurology
Northwestern University
Feinberg School of Medicine
Director
Northwestern Comprehensive Multiple Sclerosis Program
Chicago, IL

Relevant Financial Disclosures
Consultant: Bristol Myers Squibb, Genentech, Mylan
Independent Research Contractor: Sanofi

Stephen Krieger, MD, FAAN
Professor of Neurology
The Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, NY

Relevant Financial Disclosures
Consultant: Biogen, EMD Serono, Genentech, Genzyme/Sanofi, Novartis, Octave, TG Therapeutics
Speaker Contracted by Ineligible Company: Biogen, EMD Serono, Genentech
Independent Research Contractor: Biogen, Bristol Myers Squibb, Novartis, Sanofi

Clyde E. Markowitz, MD
Associate Professor of Neurology
Emeritus Director, Multiple Sclerosis Center
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Relevant Financial Disclosures
Consultant: Alexion, ANI Pharmaceuticals, Banner Life Sciences, Biogen, Bristol Myers Squibb, EMD Serono, Genentech/Roche, Genzyme/Sanofi, Janssen/Actelion, Novartis, Teva, TG Therapeutics

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Relationship information is accurate at the time of content development.

Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial relationships to disclose.

Amy Perrin Ross, APN, MSN, CNRN, MSCN
Consultant: Alexion, Bristol Myers Squibb, EMD Serono, Genentech, Genzyme, Janssen, Novartis, TG Therapeutics

Speaker Contracted by Ineligible Company: Alexion, EMD Serono, Genentech, Genzyme, Janssen

Vindico Medical Education Staff:
No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide a maximum of 1.75 contact hours for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

This enduring material is approved for 1 year from the date of original release, November 30, 2022, to November 29, 2023.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or ANCC Contact Hour Certificate.

Statement of Commercial Support

This activity is supported by educational grants from EMD Serono, Inc. and Genentech, a member of the Roche Group.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

Contact Information for Questions About the Activity

CE Questions?
Contact us at CME@VindicoCME.com

Activity Details

Free CME/CNE
1.75 AMA PRA Category 1 Credit(s)
1.75 ANCC Contact Hour(s)
Released: November 30, 2022
Expires: November 29, 2023
1.75 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, neurology nurses, neurology nurse practitioners, and other health care professionals involved in the management of patients with multiple sclerosis (MS).

Learning Objectives

Physicians and APPs
Upon successful completion of this activity, physicians should be better able to:

  1. Assess the most recent clinical and/or real-world evidence regarding the safety and efficacy of current and emerging disease-modifying therapies (DMTs) for the treatment of patients with MS.
  2. Identify clinical trends and controversies in MS that may have implications on clinical decision-making.
  3. Review data regarding the impact of DMTs on overall immune response to vaccines (including non-COVID-19 vaccines) into clinical decision-making.

Nurses
Upon successful completion of this activity, nurses should be better able to:

  1. Assess the most recent clinical and/or real-world evidence regarding the safety and efficacy of current and emerging DMTs for the treatment of patients with MS.
  2. Identify clinical trends and controversies in MS that may have implications on clinical decision-making.
  3. Review data regarding the impact of DMTs on overall immune response to vaccines (including non-COVID-19 vaccines) into clinical decision-making.

Activity Description

Multiple sclerosis (MS) is a chronic, often disabling disease that attacks the central nervous system. The management of patients with MS is highly complex, and the development of disease-modifying therapies (DMTs) has dramatically altered the treatment paradigm. The live, virtual “MS Forum® VIII: Advancing MS Care in the Pandemic Era” is a 3-part, multi-accredited webinar series that aims to provide health care professionals with guidance on the appropriate use of therapies and strategies for delivering individualized care to patients with MS. This session will incorporate didactic and case presentations covering vaccines in MS, differentiating DMTs, novel advances in MS, as well as a focus on Bruton tyrosine kinase inhibitors.

Agenda

Introduction – Overview of objectives and activation of learning
Patricia K. Coyle, MD

The Year in Review: Novel Advances in MS
Clyde E. Markowitz, MD

Vaccines in MS: Immunization Protocols in Patients With MS
Bruce A. Cohen, MD

Clinical Cases: Vaccination Vacillation
Bruce A. Cohen, MD

Differentiating DMTs to Optimize Treatment Individualization
Stephen Krieger, MD

Focus on BTK Inhibitors: Clinical Updates
Patricia K. Coyle, MD

Clinical Case: Selecting Optimal Treatment for a Patient With MS
Patricia K. Coyle, MD

Activity Chair

Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Stony Brook MS Comprehensive Care Center
Stony Brook University
Stony Brook, NY

Relevant Financial Disclosures
Consultant: Accordant, Biogen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Mylan, Novartis, Sanofi, TG Therapeutics
Independent Research Contractor: Actelion, Alkermes, Celgene, Genentech/Roche, Novartis, Sanofi Genzyme

Faculty

Bruce A. Cohen, MD, FAAN, FANA, FACP
Professor of Neurology
Northwestern University
Feinberg School of Medicine
Director
Northwestern Comprehensive Multiple Sclerosis Program
Chicago, IL

Relevant Financial Disclosures
Consultant: Bristol Myers Squibb, Genentech, Mylan
Independent Research Contractor: Sanofi

Stephen Krieger, MD, FAAN
Professor of Neurology
The Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, NY

Relevant Financial Disclosures
Consultant: Biogen, EMD Serono, Genentech, Genzyme/Sanofi, Novartis, Octave, TG Therapeutics
Speaker Contracted by Ineligible Company: Biogen, EMD Serono, Genentech
Independent Research Contractor: Biogen, Bristol Myers Squibb, Novartis, Sanofi

Clyde E. Markowitz, MD
Associate Professor of Neurology
Emeritus Director, Multiple Sclerosis Center
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Relevant Financial Disclosures
Consultant: Alexion, ANI Pharmaceuticals, Banner Life Sciences, Biogen, Bristol Myers Squibb, EMD Serono, Genentech/Roche, Genzyme/Sanofi, Janssen/Actelion, Novartis, Teva, TG Therapeutics

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Relationship information is accurate at the time of content development.

Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial relationships to disclose.

Amy Perrin Ross, APN, MSN, CNRN, MSCN
Consultant: Alexion, Bristol Myers Squibb, EMD Serono, Genentech, Genzyme, Janssen, Novartis, TG Therapeutics

Speaker Contracted by Ineligible Company: Alexion, EMD Serono, Genentech, Genzyme, Janssen

Vindico Medical Education Staff:
No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide a maximum of 1.75 contact hours for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

This enduring material is approved for 1 year from the date of original release, November 30, 2022, to November 29, 2023.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or ANCC Contact Hour Certificate.

Statement of Commercial Support

This activity is supported by educational grants from EMD Serono, Inc. and Genentech, a member of the Roche Group.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

Contact Information for Questions About the Activity

CE Questions?
Contact us at CME@VindicoCME.com

1.75 CME / CNE
Vindico Medical Education
MS Forum® VIII: Biomarkers, Imaging, and Gender-Based Issues in MS

MS Forum® VIII: Biomarkers, Imaging, and Gender-Based Issues in MS

Start

Activity Details

Free CME/CNE
1.75 AMA PRA Category 1 Credit(s)
1.75 ANCC Contact Hour(s)
Released: November 30, 2022
Expires: November 29, 2023
1.75 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, neurology nurses, neurology nurse practitioners, and other health care professionals involved in the management of patients with multiple sclerosis (MS).

Learning Objectives

Physicians and APPs
Upon successful completion of this activity, physicians should be better able to:

  1. Identify clinical trends and controversies in MS that may have implications on clinical decision-making.
  2. Utilize strategies for the early identification of patients with relapsing-remitting MS (RRMS) or progressive MS to facilitate timely intervention.
  3. Incorporate knowledge of the benefit/risk profiles of disease modifying therapies (DMTs), including COVID-19-related safety issues, when making decisions about early treatment for patients with MS.
  4. Examine the role of shared decision-making and strategies to improve patient-provider communication regarding the disease state and selection of optimal DMTs in alignment with patient preferences.

Nurses
Upon successful completion of this activity, nurses should be better able to:

  1. Identify clinical trends and controversies in MS that may have implications on clinical decision-making.
  2. Examine the role of shared decision-making and strategies to improve patient-provider communication regarding the disease state and selection of optimal DMTs in alignment with patient preferences.

Activity Description

Multiple sclerosis (MS) is a chronic, often disabling disease that attacks the central nervous system. The management of patients with MS is highly complex, and the development of disease-modifying therapies (DMTs) has dramatically altered the treatment paradigm. The live, virtual “MS Forum® VIII: Advancing MS Care in the Pandemic Era” is a 3-part, multi-accredited webinar series that aims to provide health care professionals with guidance on the appropriate use of therapies and strategies for delivering individualized care to patients with MS. This session will incorporate didactic presentations and case presentations covering imaging and biomarkers, gender-based issues in patients with MS, as well as a series of TED talks on where the field is now and where it is heading. 

Agenda

Introduction
Patricia K. Coyle, MD

Updates in Imaging and Biomarkers
Clyde E. Markowitz, MD

Gender-Based Issues in MS
Patricia K. Coyle, MD

Clinical Case: Journey of a Female MS Patient Through the Various Phases of the Family Planning Process
Patricia K. Coyle, MD

TED Talks in MS: Where We Are, Where We’re Headed
Moderated by Bruce A. Cohen, MD, and Clyde E. Markowitz, MD

Panel Discussion
All Faculty

Activity Chair

Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Stony Brook MS Comprehensive Care Center
Stony Brook University
Stony Brook, NY

Relevant Financial Disclosures
Consultant: Accordant, Biogen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Mylan, Novartis, Sanofi, TG Therapeutics
Independent Research Contractor: Actelion, Alkermes, Celgene, Genentech/Roche, Novartis, Sanofi Genzyme

Faculty

Bruce A. Cohen, MD, FAAN, FANA, FACP
Professor of Neurology
Northwestern University
Feinberg School of Medicine
Director
Northwestern Comprehensive Multiple Sclerosis Program
Chicago, IL

Relevant Financial Disclosures
Consultant: Bristol Myers Squibb, Genentech, Mylan
Independent Research Contractor: Sanofi

Clyde E. Markowitz, MD
Associate Professor of Neurology
Emeritus Director, Multiple Sclerosis Center
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Relevant Financial Disclosures
Consultant: Alexion, ANI Pharmaceuticals, Banner Life Sciences, Biogen, Bristol Myers Squibb, EMD Serono, Genentech/Roche, Genzyme/Sanofi, Janssen/Actelion, Novartis, Teva, TG Therapeutics

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Relationship information is accurate at the time of content development.

Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial relationships to disclose.

Amy Perrin Ross, APN, MSN, CNRN, MSCN
Consultant: Alexion, Bristol Myers Squibb, EMD Serono, Genentech, Genzyme, Janssen, Novartis, TG Therapeutics

Speaker Contracted by Ineligible Company: Alexion, EMD Serono, Genentech, Genzyme, Janssen

Vindico Medical Education Staff:
No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide a maximum of 1.75 contact hours for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

This enduring material is approved for 1 year from the date of original release, November 30, 2022, to November 29, 2023.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 80% of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or ANCC Contact Hour Certificate.

Statement of Commercial Support

This activity is supported by educational grants from EMD Serono, Inc. and Genentech, a member of the Roche Group.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

Contact Information for Questions About the Activity

CE Questions?
Contact us at CME@VindicoCME.com

Activity Details

Free CME/CNE
1.75 AMA PRA Category 1 Credit(s)
1.75 ANCC Contact Hour(s)
Released: November 30, 2022
Expires: November 29, 2023
1.75 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, neurology nurses, neurology nurse practitioners, and other health care professionals involved in the management of patients with multiple sclerosis (MS).

Learning Objectives

Physicians and APPs
Upon successful completion of this activity, physicians should be better able to:

  1. Identify clinical trends and controversies in MS that may have implications on clinical decision-making.
  2. Utilize strategies for the early identification of patients with relapsing-remitting MS (RRMS) or progressive MS to facilitate timely intervention.
  3. Incorporate knowledge of the benefit/risk profiles of disease modifying therapies (DMTs), including COVID-19-related safety issues, when making decisions about early treatment for patients with MS.
  4. Examine the role of shared decision-making and strategies to improve patient-provider communication regarding the disease state and selection of optimal DMTs in alignment with patient preferences.

Nurses
Upon successful completion of this activity, nurses should be better able to:

  1. Identify clinical trends and controversies in MS that may have implications on clinical decision-making.
  2. Examine the role of shared decision-making and strategies to improve patient-provider communication regarding the disease state and selection of optimal DMTs in alignment with patient preferences.

Activity Description

Multiple sclerosis (MS) is a chronic, often disabling disease that attacks the central nervous system. The management of patients with MS is highly complex, and the development of disease-modifying therapies (DMTs) has dramatically altered the treatment paradigm. The live, virtual “MS Forum® VIII: Advancing MS Care in the Pandemic Era” is a 3-part, multi-accredited webinar series that aims to provide health care professionals with guidance on the appropriate use of therapies and strategies for delivering individualized care to patients with MS. This session will incorporate didactic presentations and case presentations covering imaging and biomarkers, gender-based issues in patients with MS, as well as a series of TED talks on where the field is now and where it is heading. 

Agenda

Introduction
Patricia K. Coyle, MD

Updates in Imaging and Biomarkers
Clyde E. Markowitz, MD

Gender-Based Issues in MS
Patricia K. Coyle, MD

Clinical Case: Journey of a Female MS Patient Through the Various Phases of the Family Planning Process
Patricia K. Coyle, MD

TED Talks in MS: Where We Are, Where We’re Headed
Moderated by Bruce A. Cohen, MD, and Clyde E. Markowitz, MD

Panel Discussion
All Faculty

Activity Chair

Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Stony Brook MS Comprehensive Care Center
Stony Brook University
Stony Brook, NY

Relevant Financial Disclosures
Consultant: Accordant, Biogen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Mylan, Novartis, Sanofi, TG Therapeutics
Independent Research Contractor: Actelion, Alkermes, Celgene, Genentech/Roche, Novartis, Sanofi Genzyme

Faculty

Bruce A. Cohen, MD, FAAN, FANA, FACP
Professor of Neurology
Northwestern University
Feinberg School of Medicine
Director
Northwestern Comprehensive Multiple Sclerosis Program
Chicago, IL

Relevant Financial Disclosures
Consultant: Bristol Myers Squibb, Genentech, Mylan
Independent Research Contractor: Sanofi

Clyde E. Markowitz, MD
Associate Professor of Neurology
Emeritus Director, Multiple Sclerosis Center
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Relevant Financial Disclosures
Consultant: Alexion, ANI Pharmaceuticals, Banner Life Sciences, Biogen, Bristol Myers Squibb, EMD Serono, Genentech/Roche, Genzyme/Sanofi, Janssen/Actelion, Novartis, Teva, TG Therapeutics

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Relationship information is accurate at the time of content development.

Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial relationships to disclose.

Amy Perrin Ross, APN, MSN, CNRN, MSCN
Consultant: Alexion, Bristol Myers Squibb, EMD Serono, Genentech, Genzyme, Janssen, Novartis, TG Therapeutics

Speaker Contracted by Ineligible Company: Alexion, EMD Serono, Genentech, Genzyme, Janssen

Vindico Medical Education Staff:
No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide a maximum of 1.75 contact hours for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

This enduring material is approved for 1 year from the date of original release, November 30, 2022, to November 29, 2023.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 80% of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or ANCC Contact Hour Certificate.

Statement of Commercial Support

This activity is supported by educational grants from EMD Serono, Inc. and Genentech, a member of the Roche Group.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

Contact Information for Questions About the Activity

CE Questions?
Contact us at CME@VindicoCME.com

2.0 CME / CNE
Vindico Medical Education
MS Forum® VIII: Updates on Progressive MS, the Patient Perspective, and MS Management in the COVID-19 Era

MS Forum® VIII: Updates on Progressive MS, the Patient Perspective, and MS Management in the COVID-19 Era

Start

Activity Details

Free CME/CNE
1.75 AMA PRA Category 1 Credit(s)
1.75 ANCC Contact Hour(s)
Released: November 30, 2022
Expires: November 29, 2023
1.75 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, neurology nurses, neurology nurse practitioners, and other health care professionals involved in the management of patients with multiple sclerosis (MS).

Learning Objectives

Physicians and APPs
Upon successful completion of this activity, physicians should be better able to:

  1. Evaluate the burden of comorbidities in patients with MS and their impact on quality of life.
  2. Identify clinical trends and controversies in MS that may have implications on clinical decision-making.
  3. Utilize strategies for the early identification of patients with relapsing-remitting MS (RRMS) or progressive MS to facilitate timely intervention.
  4. Determine treatment for patients with RRMS or progressive MS based on evidence-based recommendations.
  5. Examine the role of shared decision-making and strategies to improve patient-provider communication regarding the disease state and selection of optimal DMTs in alignment with patient preferences.

Nurses
Upon successful completion of this activity, nurses should be better able to:

  1. Evaluate the burden of comorbidities in patients with MS and their impact on quality of life.
  2. Identify clinical trends and controversies in MS that may have implications on clinical decision-making.
  3. Examine the role of shared decision-making and strategies to improve patient-provider communication regarding the disease state and selection of optimal DMTs in alignment with patient preferences.

Activity Description

Multiple sclerosis (MS) is a chronic, often disabling disease that attacks the central nervous system. The management of patients with MS is highly complex, and the development of disease-modifying therapies (DMTs) has dramatically altered the treatment paradigm. The live, virtual “MS Forum® VIII: Advancing MS Care in the Pandemic Era” is a 3-part, multi-accredited webinar series that aims to provide health care professionals with guidance on the appropriate use of therapies and strategies for delivering individualized care to patients with MS. This session will incorporate didactic presentations and case presentations covering the effect of environmental factors and comorbidities in patients with MS, advances in progressive MS, as well as rapid-fire controversies in MS. This session will also feature the patient perspective, with video segments of a patient with MS addressing common concerns and the role of shared decision-making. 

Agenda

Introduction
Patricia K. Coyle, MD

Patient Perspectives in MS
Patricia K. Coyle, MD and Dana Hernandez

Advances in Progressive MS: Optimizing Patient Recognition and Treatment
Clyde E. Markowitz, MD

Clinical Case 1: Optimizing Treatment of a Patient With Progressive MS
Clyde E. Markowitz, MD  

Effect of Environmental Factors and Comorbidities: Impact on MS Care
Bruce A. Cohen, MD

Rapid-Fire Controversies in MS
Stephen Krieger, MD

Clinical Case 2: Managing MS Patient in the COVID-19 Era – Tying It All Together
Patricia K. Coyle, MD, FAAN, FANA

Panel Discussion
All Faculty

Activity Chair

Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Stony Brook MS Comprehensive Care Center
Stony Brook University
Stony Brook, NY

Relevant Financial Disclosures
Consultant: Accordant, Biogen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Mylan, Novartis, Sanofi, TG Therapeutics
Independent Research Contractor: Actelion, Alkermes, Celgene, Genentech/Roche, Novartis, Sanofi Genzyme

Faculty

Bruce A. Cohen, MD, FAAN, FANA, FACP
Professor of Neurology
Northwestern University
Feinberg School of Medicine
Director
Northwestern Comprehensive Multiple Sclerosis Program
Chicago, IL

Relevant Financial Disclosures
Consultant: Bristol Myers Squibb, Genentech, Mylan
Independent Research Contractor: Sanofi

Stephen Krieger, MD, FAAN
Professor of Neurology
The Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, NY

Relevant Financial Disclosures
Consultant: Biogen, EMD Serono, Genentech, Genzyme/Sanofi, Novartis, Octave, TG Therapeutics
Speaker Contracted by Ineligible Company: Biogen, EMD Serono, Genentech
Independent Research Contractor: Biogen, Bristol Myers Squibb, Novartis, Sanofi

Clyde E. Markowitz, MD
Associate Professor of Neurology
Emeritus Director, Multiple Sclerosis Center
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Relevant Financial Disclosures
Consultant: Alexion, ANI Pharmaceuticals, Banner Life Sciences, Biogen, Bristol Myers Squibb, EMD Serono, Genentech/Roche, Genzyme/Sanofi, Janssen/Actelion, Novartis, Teva, TG Therapeutics

Patient

Dana Hernandez, MBA
No relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Relationship information is accurate at the time of content development.

Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial relationships to disclose.

Amy Perrin Ross, APN, MSN, CNRN, MSCN
Consultant: Alexion, Bristol Myers Squibb, EMD Serono, Genentech, Genzyme, Janssen, Novartis, TG Therapeutics

Speaker Contracted by Ineligible Company: Alexion, EMD Serono, Genentech, Genzyme, Janssen

Vindico Medical Education Staff:
No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide a maximum of 1.75 contact hours for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

This enduring material is approved for 1 year from the date of original release, November 30, 2022, to November 29, 2023.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or ANCC Contact Hour Certificate.

Statement of Commercial Support

This activity is supported by educational grants from EMD Serono, Inc. and Genentech, a member of the Roche Group.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

Contact Information for Questions About the Activity

CE Questions?
Contact us at CME@VindicoCME.com

Activity Details

Free CME/CNE
1.75 AMA PRA Category 1 Credit(s)
1.75 ANCC Contact Hour(s)
Released: November 30, 2022
Expires: November 29, 2023
1.75 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, neurology nurses, neurology nurse practitioners, and other health care professionals involved in the management of patients with multiple sclerosis (MS).

Learning Objectives

Physicians and APPs
Upon successful completion of this activity, physicians should be better able to:

  1. Evaluate the burden of comorbidities in patients with MS and their impact on quality of life.
  2. Identify clinical trends and controversies in MS that may have implications on clinical decision-making.
  3. Utilize strategies for the early identification of patients with relapsing-remitting MS (RRMS) or progressive MS to facilitate timely intervention.
  4. Determine treatment for patients with RRMS or progressive MS based on evidence-based recommendations.
  5. Examine the role of shared decision-making and strategies to improve patient-provider communication regarding the disease state and selection of optimal DMTs in alignment with patient preferences.

Nurses
Upon successful completion of this activity, nurses should be better able to:

  1. Evaluate the burden of comorbidities in patients with MS and their impact on quality of life.
  2. Identify clinical trends and controversies in MS that may have implications on clinical decision-making.
  3. Examine the role of shared decision-making and strategies to improve patient-provider communication regarding the disease state and selection of optimal DMTs in alignment with patient preferences.

Activity Description

Multiple sclerosis (MS) is a chronic, often disabling disease that attacks the central nervous system. The management of patients with MS is highly complex, and the development of disease-modifying therapies (DMTs) has dramatically altered the treatment paradigm. The live, virtual “MS Forum® VIII: Advancing MS Care in the Pandemic Era” is a 3-part, multi-accredited webinar series that aims to provide health care professionals with guidance on the appropriate use of therapies and strategies for delivering individualized care to patients with MS. This session will incorporate didactic presentations and case presentations covering the effect of environmental factors and comorbidities in patients with MS, advances in progressive MS, as well as rapid-fire controversies in MS. This session will also feature the patient perspective, with video segments of a patient with MS addressing common concerns and the role of shared decision-making. 

Agenda

Introduction
Patricia K. Coyle, MD

Patient Perspectives in MS
Patricia K. Coyle, MD and Dana Hernandez

Advances in Progressive MS: Optimizing Patient Recognition and Treatment
Clyde E. Markowitz, MD

Clinical Case 1: Optimizing Treatment of a Patient With Progressive MS
Clyde E. Markowitz, MD  

Effect of Environmental Factors and Comorbidities: Impact on MS Care
Bruce A. Cohen, MD

Rapid-Fire Controversies in MS
Stephen Krieger, MD

Clinical Case 2: Managing MS Patient in the COVID-19 Era – Tying It All Together
Patricia K. Coyle, MD, FAAN, FANA

Panel Discussion
All Faculty

Activity Chair

Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Stony Brook MS Comprehensive Care Center
Stony Brook University
Stony Brook, NY

Relevant Financial Disclosures
Consultant: Accordant, Biogen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Mylan, Novartis, Sanofi, TG Therapeutics
Independent Research Contractor: Actelion, Alkermes, Celgene, Genentech/Roche, Novartis, Sanofi Genzyme

Faculty

Bruce A. Cohen, MD, FAAN, FANA, FACP
Professor of Neurology
Northwestern University
Feinberg School of Medicine
Director
Northwestern Comprehensive Multiple Sclerosis Program
Chicago, IL

Relevant Financial Disclosures
Consultant: Bristol Myers Squibb, Genentech, Mylan
Independent Research Contractor: Sanofi

Stephen Krieger, MD, FAAN
Professor of Neurology
The Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, NY

Relevant Financial Disclosures
Consultant: Biogen, EMD Serono, Genentech, Genzyme/Sanofi, Novartis, Octave, TG Therapeutics
Speaker Contracted by Ineligible Company: Biogen, EMD Serono, Genentech
Independent Research Contractor: Biogen, Bristol Myers Squibb, Novartis, Sanofi

Clyde E. Markowitz, MD
Associate Professor of Neurology
Emeritus Director, Multiple Sclerosis Center
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Relevant Financial Disclosures
Consultant: Alexion, ANI Pharmaceuticals, Banner Life Sciences, Biogen, Bristol Myers Squibb, EMD Serono, Genentech/Roche, Genzyme/Sanofi, Janssen/Actelion, Novartis, Teva, TG Therapeutics

Patient

Dana Hernandez, MBA
No relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Relationship information is accurate at the time of content development.

Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial relationships to disclose.

Amy Perrin Ross, APN, MSN, CNRN, MSCN
Consultant: Alexion, Bristol Myers Squibb, EMD Serono, Genentech, Genzyme, Janssen, Novartis, TG Therapeutics

Speaker Contracted by Ineligible Company: Alexion, EMD Serono, Genentech, Genzyme, Janssen

Vindico Medical Education Staff:
No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide a maximum of 1.75 contact hours for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

This enduring material is approved for 1 year from the date of original release, November 30, 2022, to November 29, 2023.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or ANCC Contact Hour Certificate.

Statement of Commercial Support

This activity is supported by educational grants from EMD Serono, Inc. and Genentech, a member of the Roche Group.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

Contact Information for Questions About the Activity

CE Questions?
Contact us at CME@VindicoCME.com

Vera Bril, MD, FRCPC
1.0 CME
The CME Institute of Physicians Postgraduate Press, Inc.
A Review of Disease Mechanisms and Current and Emerging Treatment Options for Generalized Myasthenia Gravis

A Review of Disease Mechanisms and Current and Emerging Treatment Options for Generalized Myasthenia Gravis

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: June 21, 2022
Expires: June 20, 2023
60 minutes to complete

Accredited By

The CME Institute of Physicians Postgraduate Press, Inc.

Target Audience

Neurology, neuromuscular, neuroimmunology, & neuro-ophthalmology advanced care practitioners in North America, Europe, and Japan

Learning Objectives

  • Consider actions of novel medications in treatment decisions for patients with gMG (including IgG and AChR antibodies, FcRn modulation)
  • Counsel patients on the changing landscape of gMG treatment
  • Incorporate evidence on efficacy and safety into the process of tailoring appropriate therapies for patients with gMG, both with current treatments and as novel ones become available

Activity Description

On-demand webcast featuring faculty presentations and case questions from the webinar.

Statement of Educational Need

Treatment of gMG is not one-size-fits-all because of patients’ varied symptoms and disease pathophysiology. Despite numerous available therapies, the current treatment landscape for gMG has left many patients with unmet efficacy needs and considerable side effect burden. Research in gMG has grown substantially in recent years. Clinicians need awareness of disease mechanisms and education on the efficacy and safety of current and emerging therapies to improve outcomes for patients with gMG. This activity was designed to meet the needs of participants in CME activities provided by the CME Institute of Physicians Postgraduate Press, Inc., who have requested information on gMG.

Chair

Vera Bril, MD, FRCPC
Division of Neurology
University of Toronto and University Health Network
Toronto, Ontario, Canada

Dr. Bril has served as a consultant for argenx, Alexion, Alnylam, Ackea, Ionis, Immunovant, Sanofi, Roche, UCB, Momenta, CSL, Takeda, Octapharma, NovoNordisk, Grifols, Janssen; received grant/research support from argenx, Alexion, UCB, Takeda, CSL, Immunovant, Momenta, Ionis, Pharnext; received honoraria from argenx, Alexion, Alnylam, Ackea, Immunovant, Momenta, Ionis, Pharnext; and has served on speakers/advisory boards for argenx, Alexion, Alnylam, Ackea, Ionis, Immunovant, Sanofi, Roche, UCB, Momenta, CSL, Takeda, Octapharma, NovoNordisk, Grifols, Janssen.

Faculty

Nicholas J. Silvestri MD, FAAN
University at Buffalo Jacobs School of Medicine and Biosciences
Buffalo, New York

Dr. Silvestri has served as a consultant for argenx and has served on speakers/advisory boards for Alexion, argenx, Immunovant, UCB, and Strongbridge.


Carolina Barnett-Tapia, MD, PhD
Division of Neurology
University of Toronto and University Health Network
Toronto, Ontario, Canada

Dr. Barnett-Tapia has served as a consultant for argenx and Alexion; received grant/research support from the US Department of Defense, MGNet, Muscular Dystrophy Canada, and Grifols; and served on the speaker/advisory board for Sanofi.

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

To obtain credit for this activity, study the material and complete the CME Posttest and Evaluation.

Instructions for Receiving Credit

In order to be awarded credit and/or a certificate for this activity, learners must study the material, participating in all course pages, complete the Posttest, and complete the Evaluation.

Statement of Commercial Support

Supported by an educational grant from argenx.

Disclaimer Statement/Disclosure of Unlabeled Use

The faculty members have determined that, to the best of their knowledge, corticosteroids, azathioprine, mycophenolate, methotrexate, cyclosporine, tacrolimus, IVIG, SCIG, PLEX, rituximab, rozanolixizumab, zilucoplan, nipocalimab, and RVT-1401 are not approved by the US Food and Drug Administration for the treatment of myasthenia gravis.

Contact Information for Questions About the Activity

cme@cmeinstitute.com

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: June 21, 2022
Expires: June 20, 2023
60 minutes to complete

Accredited By

The CME Institute of Physicians Postgraduate Press, Inc.

Target Audience

Neurology, neuromuscular, neuroimmunology, & neuro-ophthalmology advanced care practitioners in North America, Europe, and Japan

Learning Objectives

  • Consider actions of novel medications in treatment decisions for patients with gMG (including IgG and AChR antibodies, FcRn modulation)
  • Counsel patients on the changing landscape of gMG treatment
  • Incorporate evidence on efficacy and safety into the process of tailoring appropriate therapies for patients with gMG, both with current treatments and as novel ones become available

Activity Description

On-demand webcast featuring faculty presentations and case questions from the webinar.

Statement of Educational Need

Treatment of gMG is not one-size-fits-all because of patients’ varied symptoms and disease pathophysiology. Despite numerous available therapies, the current treatment landscape for gMG has left many patients with unmet efficacy needs and considerable side effect burden. Research in gMG has grown substantially in recent years. Clinicians need awareness of disease mechanisms and education on the efficacy and safety of current and emerging therapies to improve outcomes for patients with gMG. This activity was designed to meet the needs of participants in CME activities provided by the CME Institute of Physicians Postgraduate Press, Inc., who have requested information on gMG.

Chair

Vera Bril, MD, FRCPC
Division of Neurology
University of Toronto and University Health Network
Toronto, Ontario, Canada

Dr. Bril has served as a consultant for argenx, Alexion, Alnylam, Ackea, Ionis, Immunovant, Sanofi, Roche, UCB, Momenta, CSL, Takeda, Octapharma, NovoNordisk, Grifols, Janssen; received grant/research support from argenx, Alexion, UCB, Takeda, CSL, Immunovant, Momenta, Ionis, Pharnext; received honoraria from argenx, Alexion, Alnylam, Ackea, Immunovant, Momenta, Ionis, Pharnext; and has served on speakers/advisory boards for argenx, Alexion, Alnylam, Ackea, Ionis, Immunovant, Sanofi, Roche, UCB, Momenta, CSL, Takeda, Octapharma, NovoNordisk, Grifols, Janssen.

Faculty

Nicholas J. Silvestri MD, FAAN
University at Buffalo Jacobs School of Medicine and Biosciences
Buffalo, New York

Dr. Silvestri has served as a consultant for argenx and has served on speakers/advisory boards for Alexion, argenx, Immunovant, UCB, and Strongbridge.


Carolina Barnett-Tapia, MD, PhD
Division of Neurology
University of Toronto and University Health Network
Toronto, Ontario, Canada

Dr. Barnett-Tapia has served as a consultant for argenx and Alexion; received grant/research support from the US Department of Defense, MGNet, Muscular Dystrophy Canada, and Grifols; and served on the speaker/advisory board for Sanofi.

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

To obtain credit for this activity, study the material and complete the CME Posttest and Evaluation.

Instructions for Receiving Credit

In order to be awarded credit and/or a certificate for this activity, learners must study the material, participating in all course pages, complete the Posttest, and complete the Evaluation.

Statement of Commercial Support

Supported by an educational grant from argenx.

Disclaimer Statement/Disclosure of Unlabeled Use

The faculty members have determined that, to the best of their knowledge, corticosteroids, azathioprine, mycophenolate, methotrexate, cyclosporine, tacrolimus, IVIG, SCIG, PLEX, rituximab, rozanolixizumab, zilucoplan, nipocalimab, and RVT-1401 are not approved by the US Food and Drug Administration for the treatment of myasthenia gravis.

Contact Information for Questions About the Activity

cme@cmeinstitute.com

Marwan Noel Sabbagh, MD, FAAN
0.5 AAFP / CME
RMEI Medical Education, LLC
The Increasingly Vital Role of Early Alzheimer’s Disease Diagnosis & Treatment in Averting the Amyloid Tipping Point

The Increasingly Vital Role of Early Alzheimer’s Disease Diagnosis & Treatment in Averting the Amyloid Tipping Point

Start

Activity Details

Free CME/AAFP
0.5 AMA PRA Category 1 Credit(s)
0.5 AAFP Prescribed Credit(s)
Released: April 15, 2022
Expires: April 14, 2023
30 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for neurology and primary care clinicians (MD/DO/NP/PA) engaged in the care of patients with Alzheimer’s disease.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify mild cognitive impairment and early Alzheimer’s disease with the help of screening tools, biomarkers, and neuroimaging techniques
  • Integrate approved and emerging anti-amyloid β therapies for the treatment of mild cognitive impairment and early-stage Alzheimer’s disease

Activity Description

Alzheimer’s disease (AD) is a growing public health concern, and as the aging population rapidly increases, so too does the number of individuals affected by AD. The recent availability of therapy for mild cognitive impairment (MCI) and early-stage AD has increased the need for early screening. In this uniquely designed, reflective activity, learners are presented with 2 cases related to AD and challenged to think about how the patients could have been better assessed/managed. A multidisciplinary discussion between a primary care physician (PCP) and neurologist will combine elements of cognitive assessment, proper screening and referral, and early management to demonstrate the critical relationship PCPs and neurologists have in identifying and managing patients with MCI/early-stage AD.

Chair

Marwan Noel Sabbagh, MD, FAAN
Professor, Neurology
Barrow Neurological Institute
Phoenix, AZ

Faculty

Warren A. Jones, MD, FAAFP
Professor Emeritus, University of Mississippi Medical Center
Chief Health Officer, The Jones Group of Mississippi
Jackson, MS

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Warren A. Jones, MD, FAAFP, has no relevant financial relationship(s) with ineligible companies to disclose.

Marwan Noel Sabbagh, MD, FAAN, has relevant financial relationships with Acadia Pharmaceuticals, Alzheon, Biogen, Cortexyme, Eisai, Eli Lilly, Genentech, KeifeRx, Qynapse, Renew Research, T3D Therapeutics (Consultant); Athira, Brain Health Inc., Cognoptix, NeuroTau, Optimal Cognitive Health Company, TransDermix, uMethod Health, Versanum (Stock/Shareholder); Clinical Options, Health and Wellness Partners (Speaker/Speaker’s Bureau); Humanix (Other: Royalties).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Prescribed Credits
The AAFP has reviewed The Increasingly Vital Role of Early Alzheimer’s Disease Diagnosis & Treatment in Averting the Amyloid Tipping Point and deemed it acceptable for up to 0.50 Enduring Materials, Self-Study AAFP Prescribed credits. Term of Approval is from 04/15/2022 to 04/14/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit(s)™ toward the AMA Physician’s Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent educational grant from Biogen MA, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/AAFP
0.5 AMA PRA Category 1 Credit(s)
0.5 AAFP Prescribed Credit(s)
Released: April 15, 2022
Expires: April 14, 2023
30 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for neurology and primary care clinicians (MD/DO/NP/PA) engaged in the care of patients with Alzheimer’s disease.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify mild cognitive impairment and early Alzheimer’s disease with the help of screening tools, biomarkers, and neuroimaging techniques
  • Integrate approved and emerging anti-amyloid β therapies for the treatment of mild cognitive impairment and early-stage Alzheimer’s disease

Activity Description

Alzheimer’s disease (AD) is a growing public health concern, and as the aging population rapidly increases, so too does the number of individuals affected by AD. The recent availability of therapy for mild cognitive impairment (MCI) and early-stage AD has increased the need for early screening. In this uniquely designed, reflective activity, learners are presented with 2 cases related to AD and challenged to think about how the patients could have been better assessed/managed. A multidisciplinary discussion between a primary care physician (PCP) and neurologist will combine elements of cognitive assessment, proper screening and referral, and early management to demonstrate the critical relationship PCPs and neurologists have in identifying and managing patients with MCI/early-stage AD.

Chair

Marwan Noel Sabbagh, MD, FAAN
Professor, Neurology
Barrow Neurological Institute
Phoenix, AZ

Faculty

Warren A. Jones, MD, FAAFP
Professor Emeritus, University of Mississippi Medical Center
Chief Health Officer, The Jones Group of Mississippi
Jackson, MS

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Warren A. Jones, MD, FAAFP, has no relevant financial relationship(s) with ineligible companies to disclose.

Marwan Noel Sabbagh, MD, FAAN, has relevant financial relationships with Acadia Pharmaceuticals, Alzheon, Biogen, Cortexyme, Eisai, Eli Lilly, Genentech, KeifeRx, Qynapse, Renew Research, T3D Therapeutics (Consultant); Athira, Brain Health Inc., Cognoptix, NeuroTau, Optimal Cognitive Health Company, TransDermix, uMethod Health, Versanum (Stock/Shareholder); Clinical Options, Health and Wellness Partners (Speaker/Speaker’s Bureau); Humanix (Other: Royalties).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Prescribed Credits
The AAFP has reviewed The Increasingly Vital Role of Early Alzheimer’s Disease Diagnosis & Treatment in Averting the Amyloid Tipping Point and deemed it acceptable for up to 0.50 Enduring Materials, Self-Study AAFP Prescribed credits. Term of Approval is from 04/15/2022 to 04/14/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit(s)™ toward the AMA Physician’s Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent educational grant from Biogen MA, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Diana P. Castro, MD
0.25 CME / CNE / IPCE
RMEI Medical Education, LLC
Challenges of Treating Adults and Late-onset SMA: A Case-based Discussion

Challenges of Treating Adults and Late-onset SMA: A Case-based Discussion

Start

Activity Details

Free CME/CNE/IPCE
0.25 AMA PRA Category 1 Credit(s)
0.25 ANCC Contact Hour(s)
0.25 IPCE Credit(s)™
Released: March 25, 2022
Expires: March 24, 2023
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for neurologists, pediatric neurologists, physical medicine and rehabilitation specialists, orthopedists, nurses (RN/NP/APN), PAs, and other clinicians involved in the care of patients with spinal muscular atrophy (SMA).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Implement evaluations and treatments for the complications of spinal muscular atrophy (SMA)
  • Integrate the unique roles of the interprofessional care team in concert with consensus guidelines and best practice recommendations for management of SMA

Activity Description

Adult and late-onset spinal muscular atrophy (SMA) present with a unique set of challenges that can make treatment a little more complex. Clinicians in the United States were surveyed to submit their challenging SMA cases and, in this activity, an interprofessional expert panel offers practical advice on the treatment of some of these cases, with special attention given to issues and technicalities specific to adults.

Chair

Diana P. Castro, MD
Associate Professor, Pediatrics and Neurology
University of Texas Southwestern
Children’s Health
Dallas, TX

Faculty

Susan Apkon, MD
Fischahs Chair, Pediatric Rehabilitation
Chief, Department of Rehabilitation
Children’s Hospital Colorado
Professor and Vice Chair, Department of Physical Medicine and Rehabilitation
University of Colorado School of Medicine
Aurora, CO


Vanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN
Nurse Practitioner, Pediatrics
Philadelphia, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty
Susan Apkon, MD, has relevant financial relationships with AveXis/Novartis, Biogen, Sarepta Therapeutics, Scholar Rock (Grant/Research Support).

Vanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN, has relevant financial relationships with AveXis/Novartis, Biogen, PTC Pharmaceuticals (Advisor); AveXis/Novartis (Speaker/Speaker’s Bureau).

Diana P. Castro, MD, has relevant financial relationships with Biogen, Genentech, Novartis, SKR (Researcher).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Biogen MA, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/CNE/IPCE
0.25 AMA PRA Category 1 Credit(s)
0.25 ANCC Contact Hour(s)
0.25 IPCE Credit(s)™
Released: March 25, 2022
Expires: March 24, 2023
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for neurologists, pediatric neurologists, physical medicine and rehabilitation specialists, orthopedists, nurses (RN/NP/APN), PAs, and other clinicians involved in the care of patients with spinal muscular atrophy (SMA).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Implement evaluations and treatments for the complications of spinal muscular atrophy (SMA)
  • Integrate the unique roles of the interprofessional care team in concert with consensus guidelines and best practice recommendations for management of SMA

Activity Description

Adult and late-onset spinal muscular atrophy (SMA) present with a unique set of challenges that can make treatment a little more complex. Clinicians in the United States were surveyed to submit their challenging SMA cases and, in this activity, an interprofessional expert panel offers practical advice on the treatment of some of these cases, with special attention given to issues and technicalities specific to adults.

Chair

Diana P. Castro, MD
Associate Professor, Pediatrics and Neurology
University of Texas Southwestern
Children’s Health
Dallas, TX

Faculty

Susan Apkon, MD
Fischahs Chair, Pediatric Rehabilitation
Chief, Department of Rehabilitation
Children’s Hospital Colorado
Professor and Vice Chair, Department of Physical Medicine and Rehabilitation
University of Colorado School of Medicine
Aurora, CO


Vanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN
Nurse Practitioner, Pediatrics
Philadelphia, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty
Susan Apkon, MD, has relevant financial relationships with AveXis/Novartis, Biogen, Sarepta Therapeutics, Scholar Rock (Grant/Research Support).

Vanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN, has relevant financial relationships with AveXis/Novartis, Biogen, PTC Pharmaceuticals (Advisor); AveXis/Novartis (Speaker/Speaker’s Bureau).

Diana P. Castro, MD, has relevant financial relationships with Biogen, Genentech, Novartis, SKR (Researcher).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Biogen MA, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Diana P. Castro, MD
0.25 CME / CNE / IPCE
RMEI Medical Education, LLC
Starting Treatment in Toddlers with SMA: Too Early? Too Late?

Starting Treatment in Toddlers with SMA: Too Early? Too Late?

Start

Activity Details

Free CME/CNE/IPCE
0.25 AMA PRA Category 1 Credit(s)
0.25 ANCC Contact Hour(s)
0.25 IPCE Credit(s)™
Released: March 11, 2022
Expires: March 10, 2023
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for neurologists, pediatric neurologists, physical medicine and rehabilitation specialists, orthopedists, nurses (RN/NP/APN), PAs, and other clinicians involved in the care of patients with spinal muscular atrophy (SMA).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Select individualized disease-modifying therapy for patients with spinal muscular atrophy (SMA)
  • Integrate the unique roles of the interprofessional care team in concert with consensus guidelines and best practice recommendations for management of SMA

Activity Description

Spinal muscular atrophy (SMA) is a devastating diagnosis that is often delivered at a very tender, young age. Not too long ago, providers had nothing to treat patients with SMA beyond supportive therapies. However, now there are 3 different disease-modifying therapies to consider. We have polled clinicians across the country to find out what challenges they are met with when managing SMA in their patients. In this activity, our faculty discuss their approach to treatment for 2 of these challenging cases, with a focus on when to initiate therapy.

Chair

Diana P. Castro, MD
Associate Professor, Pediatrics and Neurology
University of Texas Southwestern
Children’s Health
Dallas, TX

Faculty

Susan Apkon, MD
Fischahs Chair, Pediatric Rehabilitation
Chief, Department of Rehabilitation
Children’s Hospital Colorado
Professor and Vice Chair, Department of Physical Medicine and Rehabilitation
University of Colorado School of Medicine
Aurora, CO

Vanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN
Nurse Practitioner, Pediatrics
Philadelphia, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty
Susan Apkon, MD, has relevant financial relationships with AveXis/Novartis, Biogen, Sarepta Therapeutics, Scholar Rock (Grant/Research Support).

Vanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN, has relevant financial relationships with AveXis/Novartis, Biogen, PTC Pharmaceuticals (Advisor); AveXis/Novartis (Speaker/Speaker’s Bureau).

Diana P. Castro, MD, has relevant financial relationships with Biogen, Genentech, Novartis, SKR (Researcher).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Biogen MA, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/CNE/IPCE
0.25 AMA PRA Category 1 Credit(s)
0.25 ANCC Contact Hour(s)
0.25 IPCE Credit(s)™
Released: March 11, 2022
Expires: March 10, 2023
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for neurologists, pediatric neurologists, physical medicine and rehabilitation specialists, orthopedists, nurses (RN/NP/APN), PAs, and other clinicians involved in the care of patients with spinal muscular atrophy (SMA).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Select individualized disease-modifying therapy for patients with spinal muscular atrophy (SMA)
  • Integrate the unique roles of the interprofessional care team in concert with consensus guidelines and best practice recommendations for management of SMA

Activity Description

Spinal muscular atrophy (SMA) is a devastating diagnosis that is often delivered at a very tender, young age. Not too long ago, providers had nothing to treat patients with SMA beyond supportive therapies. However, now there are 3 different disease-modifying therapies to consider. We have polled clinicians across the country to find out what challenges they are met with when managing SMA in their patients. In this activity, our faculty discuss their approach to treatment for 2 of these challenging cases, with a focus on when to initiate therapy.

Chair

Diana P. Castro, MD
Associate Professor, Pediatrics and Neurology
University of Texas Southwestern
Children’s Health
Dallas, TX

Faculty

Susan Apkon, MD
Fischahs Chair, Pediatric Rehabilitation
Chief, Department of Rehabilitation
Children’s Hospital Colorado
Professor and Vice Chair, Department of Physical Medicine and Rehabilitation
University of Colorado School of Medicine
Aurora, CO

Vanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN
Nurse Practitioner, Pediatrics
Philadelphia, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty
Susan Apkon, MD, has relevant financial relationships with AveXis/Novartis, Biogen, Sarepta Therapeutics, Scholar Rock (Grant/Research Support).

Vanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN, has relevant financial relationships with AveXis/Novartis, Biogen, PTC Pharmaceuticals (Advisor); AveXis/Novartis (Speaker/Speaker’s Bureau).

Diana P. Castro, MD, has relevant financial relationships with Biogen, Genentech, Novartis, SKR (Researcher).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Biogen MA, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Diana P. Castro, MD
0.5 CME / CNE / IPCE
RMEI Medical Education, LLC
When Small Steps are GIANT LEAPS: Treating Spinal Muscular Atrophy

When Small Steps are GIANT LEAPS: Treating Spinal Muscular Atrophy

Start

Activity Details

Free CME/CNE/IPCE
0.5 AMA PRA Category 1 Credit(s)
0.5 ANCC Contact Hour(s)
0.5 IPCE Credit(s)™
Released: February 25, 2022
Expires: February 24, 2023
30 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for neurologists, pediatric neurologists, physical medicine and rehabilitation specialists, orthopedists, nurses (RN/NP/APN), PAs, and other clinicians involved in the care of patients with spinal muscular atrophy (SMA).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Implement evaluations and treatments for the complications of spinal muscular atrophy (SMA)
  • Select individualized disease-modifying therapy for patients with SMA
  • Integrate the unique roles of the interprofessional care team in concert with consensus guidelines and best practice recommendations for management of SMA

Activity Description

Raul’s mother insisted something was wrong, but the pediatrician assured her he was healthy and fine. After a few physical therapy sessions and testing, he was referred to a neurologist and diagnosed with spinal muscular atrophy (SMA). Today we feature Raul, his mother, his neurologist, and an interprofessional panel to discuss SMA, its biomechanical and orthopedic complications, choosing between disease-modifying therapies, and how, when it comes to the interprofessional care of patients with SMA, it truly takes a village.

Chair

Diana P. Castro, MD
Associate Professor, Pediatrics and Neurology
University of Texas Southwestern
Children’s Health
Dallas, TX


Faculty

Susan Apkon, MD
Fischahs Chair, Pediatric Rehabilitation
Chief, Department of Rehabilitation
Children’s Hospital Colorado
Professor and Vice Chair, Department of Physical Medicine and Rehabilitation
University of Colorado School of Medicine
Aurora, CO


Vanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN
Nurse Practitioner, Pediatrics
Philadelphia, PA


Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty
Susan Apkon, MD, has relevant financial relationship(s) with AveXis/Novartis, Biogen, Sarepta Therapeutics, Scholar Rock (Grant/Research Support).

Vanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN, has relevant financial relationships with AveXis/Novartis, Biogen, PTC Pharmaceuticals (Advisor); AveXis/Novartis (Speaker/Speaker’s Bureau).

Diana P. Castro, MD, has relevant financial relationships with Biogen, Genentech, Novartis, SKR (Researcher).

Patient and Caregiver
Patient and caregiver participating in this activity have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Biogen MA, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/CNE/IPCE
0.5 AMA PRA Category 1 Credit(s)
0.5 ANCC Contact Hour(s)
0.5 IPCE Credit(s)™
Released: February 25, 2022
Expires: February 24, 2023
30 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for neurologists, pediatric neurologists, physical medicine and rehabilitation specialists, orthopedists, nurses (RN/NP/APN), PAs, and other clinicians involved in the care of patients with spinal muscular atrophy (SMA).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Implement evaluations and treatments for the complications of spinal muscular atrophy (SMA)
  • Select individualized disease-modifying therapy for patients with SMA
  • Integrate the unique roles of the interprofessional care team in concert with consensus guidelines and best practice recommendations for management of SMA

Activity Description

Raul’s mother insisted something was wrong, but the pediatrician assured her he was healthy and fine. After a few physical therapy sessions and testing, he was referred to a neurologist and diagnosed with spinal muscular atrophy (SMA). Today we feature Raul, his mother, his neurologist, and an interprofessional panel to discuss SMA, its biomechanical and orthopedic complications, choosing between disease-modifying therapies, and how, when it comes to the interprofessional care of patients with SMA, it truly takes a village.

Chair

Diana P. Castro, MD
Associate Professor, Pediatrics and Neurology
University of Texas Southwestern
Children’s Health
Dallas, TX


Faculty

Susan Apkon, MD
Fischahs Chair, Pediatric Rehabilitation
Chief, Department of Rehabilitation
Children’s Hospital Colorado
Professor and Vice Chair, Department of Physical Medicine and Rehabilitation
University of Colorado School of Medicine
Aurora, CO


Vanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN
Nurse Practitioner, Pediatrics
Philadelphia, PA


Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty
Susan Apkon, MD, has relevant financial relationship(s) with AveXis/Novartis, Biogen, Sarepta Therapeutics, Scholar Rock (Grant/Research Support).

Vanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN, has relevant financial relationships with AveXis/Novartis, Biogen, PTC Pharmaceuticals (Advisor); AveXis/Novartis (Speaker/Speaker’s Bureau).

Diana P. Castro, MD, has relevant financial relationships with Biogen, Genentech, Novartis, SKR (Researcher).

Patient and Caregiver
Patient and caregiver participating in this activity have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Biogen MA, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.